Lifecore Biomedical, Inc. LFCR Weighted Average Exercise Price of Outstanding Options
Weighted Average Exercise Price of Outstanding Options at other companies
Other financials
Where this comes from
Reported directly by Lifecore Biomedical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.
The official record: Lifecore Biomedical, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lifecore Biomedical, Inc.'s weighted average exercise price of outstanding options.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lifecore Biomedical, Inc.'s weighted average exercise price of outstanding options?
- Lifecore Biomedical, Inc. (LFCR) reported weighted average exercise price of outstanding options of $7.84 in Q1 2026.
- What is the long-term trend for Lifecore Biomedical, Inc.'s weighted average exercise price of outstanding options?
- Over 2 years (2023 to 2026), Lifecore Biomedical, Inc.'s weighted average exercise price of outstanding options has grown at a -15.1% compound annual growth rate (CAGR), from $10.88 to $7.84.
- What does weighted average exercise price of outstanding options mean?
- This metric calculates the average price at which holders of outstanding stock options can purchase company shares. It provides context on the 'in-the-money' status of employee compensation packages. When compared to the current market price, it helps assess the alignment between employee incentives and shareholder value.